

Moving Document to Content Management & Authoring:

Steps for Change

Donald Palmer, RAC

MedImmune

Assoc. Director, Regulatory
Knowledge & Information Management

October 9, 2012

The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ("DIA"), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated.


These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.

Continuous Improvement



“There are three kinds of mathematicians; those who can count and those who can't.”
Anonymous

- **Why Move to Content Management?**
- **Re-Use & Content Management**
- **Tracking & Metrics**
- **Summary**



Why Move to Content Management?




- **Labeling**
 - Core Data Sheet mapped to Package Labeling
- **Global Dossier Re-Use**
 - Global Dossier – similar content, different dossiers
- **Module 3 - CMC**
 - Granularity – same content, different sized documents
- **Health Authority Q & A, Correspondence**
 - Track Qs & As by Content
 - Track Qs & As by Health Authority

Consistency of Information

Labeling: Core Data Sheet


(example)



Consistency of Translation

Labeling: Translation

(example)



Europe

Canada

USA

- EU 3.2.P Drug Product
 - P.1 Description and Composition of the Drug Product
 - P.2 Pharmaceutical Development
 - P.3.1 Manufacturer(s) of Drug Product
 - P.3.2 Batch Formula for Drug Product
 - P.3.3 Description of Manufacturing Process and Process Controls
 - P.3.4 Controls of Critical Steps and Intermediates for Drug Product
 - P.3.5 Process Validation and-or Evaluation for Drug Product
 - P.4.1 Specifications for Excipients
 - P.4.5 Excipients of Human or Animal Origin
 - P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - P.5.4 Batch Analyses for Drug Product
 - P.5.6 Justification of Specifications for Drug Product
 - P.7 Container Closure System for Drug Product
 - P.7 Specification for Blister
 - P.8.1 Stability Summary for Drug Product
 - P.8.1 Stability Conclusion for Drug Product
 - P.8.2 Post-approval Stability Protocol and Stability Commitment
 - P.8.3 Stability Data for Drug Product

Upload to eCTD

- Canada 3.2.P Drug Product
 - P.1 Description and Composition of the Drug Product
 - P.2 Pharmaceutical Development
 - CA P.3.1 Manufacturer(s) of Drug Product
 - P.3.2 Batch Formula for Drug Product
 - P.3.3 Description of Manufacturing Process and Process Controls
 - P.3.4 Controls of Critical Steps and Intermediates for Drug Product
 - P.3.5 Process Validation and-or Evaluation for Drug Product
 - P.4.1 Specifications for Excipients
 - P.4.5 Excipients of Human or Animal Origin
 - P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - P.5.4 Batch Analyses for Drug Product
 - P.5.6 Justification of Specifications for Drug Product
 - CA P.7 Container Closure System for Drug Product
 - P.7 Specification for Blister
 - P.8.1 Stability Summary for Drug Product
 - CA P.8.1 Stability Conclusion for Drug Product
 - P.8.2 Post-approval Stability Protocol and Stability Commitment
 - P.8.3 Stability Data for Drug Product

Upload to eCTD

- US 3.2.P Drug Product
 - US P.1 Description and Composition of the Drug Product
 - P.2 Pharmaceutical Development
 - US P.3.1 Manufacturer(s) of Drug Product
 - P.3.2 Batch Formula for Drug Product
 - P.3.3 Description of Manufacturing Process and Process Controls
 - P.3.4 Controls of Critical Steps and Intermediates for Drug Product
 - US P.3.5 Process Validation and-or Evaluation for Drug Product
 - P.4.1 Specifications for Excipients
 - P.4.5 Excipients of Human or Animal Origin
 - US P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - US P.5.4 Batch Analyses for Drug Product
 - US P.5.6 Justification of Specifications for Drug Product
 - US P.7 Container Closure System for Drug Product
 - US P.7 Specification for Bottle
 - US P.7 Manufacturer for Bottle
 - US P.8.1 Stability Summary for Drug Product
 - US P.8.1 Stability Conclusion for Drug Product
 - US P.8.2 Post-approval Stability Protocol and Stability Commitment
 - US P.8.3 Stability Data for Drug Product

Upload to eCTD

International

- International 3.2.P Drug Product
 - IQD P.1 Description and Composition of the Drug Product
 - IQD P.2 Pharmaceutical Development
 - IQD P.3.1 Manufacturer(s) of Drug Product
 - P.3.2 Batch Formula for Drug Product
 - IQD P.3.3 Description of Manufacturing Process and Process Controls
 - IQD P.4.1 Specifications for Excipients
 - P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - IQD P.7 Container Closure System for Drug Product
 - P.7 Specification for Blister
 - P.8.1 Stability Summary for Drug Product
 - IQD P.8.1 Stability Conclusion for Drug Product
 - IQD P.8.3 Stability Data for Drug Product

References
only to Ph Eur

ASEAN

- ASEAN 3.2.P Drug Product
 - P.1 Description and Composition of the Drug Product
 - ASEAN P.2 Pharmaceutical Development
 - ASEAN P.3.1 Batch Formula for Drug Product
 - ASEAN P.3.2 Description of Manufacturing Process and Process Control
 - ASEAN P.3.3 Control of Critical Steps and Intermediates
 - ASEAN Process Validation Annex 1
 - P.3.4 Controls of Critical Steps and Intermediates for Drug Product
 - P.4.1 Specifications for Excipients
 - ASEAN P.4.3 Excipients of Human or Animal Origin
 - P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - P.5.4 Batch Analyses for Drug Product
 - P.5.6 Justification of Specifications for Drug Product
 - P.7 Container Closure System for Drug Product
 - P.7 Specification for Blister
 - ASEAN Stability Annex 1
 - P.8.1 Stability Summary for Drug Product
 - P.8.1 Stability Conclusion for Drug Product
 - P.8.2 Post-approval Stability Protocol and Stability Commitment
 - P.8.3 Stability Data for Drug Product

Different numbering
Additional documents

China



- China CTA Item 10.2 Drug Product
 - P.5.1 Specifications
 - P.5.2 Analytical Procedure Description
 - P.5.2 Analytical Procedure Assay
 - P.5.2 Analytical Procedure Dissolution
 - P.5.3 Validation of Analytical Procedure for Assay
 - P.5.3 Validation of Analytical Procedure for Dissolution
 - P.5.4 Batch Analyses

Different
organisation
(as 'Items')

Health Authority Q & A, Correspondence



**Original Qs from
Health Authority**



Response to Original Questions




**Clarify Qs from
Health Authority**




Response to Clarification Questions

Continuous Improvement





- **Why Move to Content Management?**
- **Re-Use & Content Management**
- **Tracking & Metrics**
- **Summary**




- **Technical Manuals vs Submission Documents**
 - Tech Manuals include highly re-useable content
 - Submission Documents less re-useable content
- **Copy&Paste Re-Use vs Tracking Re-Use**
 - Re-Use via Copy&Paste loses tracking From
 - Need Re-Use as traceable content

Re-Use: Tech Manuals vs Submission Docs



- **Technical manuals have high re-use**
 - ◆ Many updates to same parts of same documents
 - ◆ Hierarchic assemblies allow for scaled re-use (re-use sets of content)

Re-Use: Tech Manuals vs Submission Docs



- **Submission documents have low re-use**
 - ♦ Few updates to same parts (Mod 3 main exception)
 - ♦ Content re-use mostly re-use of same sections to different documents, not strictly hierarchic


- **Re-usability (quality and consistency):**

- ♦ Not caught out by changes that have implications on other documents' content
- ♦ More efficient generation of Module 2.3 Quality Overall Summary
- ♦ Establishment of databases for common information
- ♦ Eliminate transcription errors

- **Potential M3 examples:**


- ♦ 3.2.S and 3.2.P flow diagrams, specifications → Module 2.3
- ♦ Container closure specification → many eCTD applications
- ♦ Manufacturing site addresses → many eCTD applications
- ♦ Facilities and Equipment → many eCTD applications
- ♦ Chemical structures → CTA (IB, IMPD), MAA (M2.3, M3)

Easy Copy & Paste: No Traceability





- **No Traceability of Content (except in Author's head)**
- **If changes made to 'Paste' side, no ability to later check if correct except via manual review**

Tagged Copy & Paste: With Traceability



- **Traceability of Content can be determined**
 - ◆ Time and Date Stamp
 - ◆ Hand-off Metrics
- **Content within tags can be:**
 - ◆ Used for regulatory & compliance purposes
 - ◆ Used for quality check purposes

Health Authority Q & A, Correspondence




Track Each Q&A Separately

- Time & Date Stamp
- Metrics

Continuous Improvement



- **Why Move to Content Management?**
- **Re-Use & Content Management**
- **Tracking & Metrics**
- **Summary**



- **Registration (incl. Q&A & Correspondence)**
- **Labeling**
- **Global Dossier & Module Re-Use**
- **Quality Component**
- **Metrics Component (Improvement)**

- **Events** track the outcome of submissions
- **Outgoing package** records which documents were sent to which country
- Monitor if submission has been
 - ◆ Dispatched, submitted, approved, withdrawn, divested
- Maintain supply links
- View data from different perspectives



**Relies on
manual input**

Thank you to Phyllis Thomas for this slide.

– Tracking:

- ◆ Reference links – update M3 content and flag for M2.3
- ◆ Track at content level instead of document level
 - By approval in 40+ countries, can have territorial variation *
- ◆ Track submissions by country
 - With XML tags can drag and drop a file on an Event to automatically recognize metadata for strength, product, dosage form, manufacturer

Thank you to Phyllis Thomas for this slide.

How is Change Tracked?

- Author holds changes and change reasons in head
- Meeting Minutes of discussions?
- What about External / Contract Authors?


How is Content Re-Use Tracked?

- Author knows where content 'copied' from
- How has content been changed when re-used?


How is Tracking Captured?

- Manual Entry into Spreadsheets
- Manual Entry into Applications (DataBase)


Tracking: Protocol to Study Report Lifecycle



Tracking & Metrics: Labeling - (Manual Entry)



Tracking & Metrics: Labeling - (Manual Entry)




How is Change Tracked?

- Tagged content changes automatically tracked through authoring workflow (internal & external)
- Tagged content, comments & edits, automatically tracked through review workflow (internal & external)

How is Content Re-Use Tracked?

- Re-Use automatically tracked through tagged content and versions
- Changed, Re-Used content automatically tracked via tagging and versions – still needs manual review for changes

Tracking & Metrics: Labeling - (Automated Entry)




- **Tracking for Management**
 - Simple Tracking – Content Structured Templates
- **Metrics For Improvement**
 - Manual collection of metrics is time consuming and error-prone
 - Ongoing Metrics gathering requires Automation
- **Workflow Automation**
 - Ongoing Metrics gathering requires Automation
- **Quality Traceability**
 - Traceability required to include Quality Component

Continuous Improvement



Summary: Moving to Content Management



- **Information needs to be managed at the Content level**
- **Re-Use is helpful – requires Content level management**
- **Tracking Content & Re-Use is better**
- **Tracking Content needs to be Automated – Workflows**
- **Auto-Tracking Content provides Metrics for Continuous Improvement**